- Home
- HRTX vs PALI Comparison
HRTX vs PALI Comparison
Compare HRTX & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- PALI
- Stock Information
- Founded
- HRTX 1983
- PALI 1996
- Country
- HRTX United States
- PALI United States
- Employees
- HRTX N/A
- PALI N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HRTX Health Care
- PALI Health Care
- Exchange
- HRTX Nasdaq
- PALI Nasdaq
- Market Cap
- HRTX 203.5M
- PALI 212.0M
- IPO Year
- HRTX 1987
- PALI N/A
- Fundamental
- Price
- HRTX $1.11
- PALI $2.16
- Analyst Decision
- HRTX Strong Buy
- PALI Strong Buy
- Analyst Count
- HRTX 2
- PALI 1
- Target Price
- HRTX $4.50
- PALI $16.00
- AVG Volume (30 Days)
- HRTX 2.1M
- PALI 4.3M
- Earning Date
- HRTX 11-04-2025
- PALI 11-10-2025
- Dividend Yield
- HRTX N/A
- PALI N/A
- EPS Growth
- HRTX N/A
- PALI N/A
- EPS
- HRTX N/A
- PALI N/A
- Revenue
- HRTX $155,097,000.00
- PALI N/A
- Revenue This Year
- HRTX $10.62
- PALI N/A
- Revenue Next Year
- HRTX $12.99
- PALI N/A
- P/E Ratio
- HRTX N/A
- PALI N/A
- Revenue Growth
- HRTX 12.60
- PALI N/A
- 52 Week Low
- HRTX $1.04
- PALI $0.53
- 52 Week High
- HRTX $2.68
- PALI $3.30
- Technical
- Relative Strength Index (RSI)
- HRTX 39.29
- PALI 60.76
- Support Level
- HRTX $1.09
- PALI $1.65
- Resistance Level
- HRTX $1.14
- PALI $2.30
- Average True Range (ATR)
- HRTX 0.07
- PALI 0.21
- MACD
- HRTX 0.00
- PALI 0.01
- Stochastic Oscillator
- HRTX 27.08
- PALI 80.19
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.